BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment
By Stephen Nakrosis
Shares of BridgeBio Oncology Therapeutics are trading higher following news the U.S. Food and Drug Administration gave fast-track designation to a treatment for certain adult patients with pancreatic cancer.
After the bell, shares of BridgeBio were trading 5.8% higher, at $9.80. The stock closed the day's regular session down nearly 1%, at $9.26.
BridgeBio's BBO-11818 is a treatment for adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma, the company said.
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial, and updated Phase 1 clinical data are expected in the second half of this year, the company added.
The fast-track designation is given to expedite the review of new drugs which target serious conditions and fill an unmet need, according to the FDA.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 20, 2026 18:53 ET (22:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States